Could a lower drug dose be safer and just as effective for kids with rare tumor?

This study compares two doses of sirolimus (low vs high) given with prednisolone to children aged 0-18 who have a rare blood vessel tumor called kaposiform hemangioendothelioma with a serious blood clotting problem (Kasabach-Merritt phenomenon). The goal is to see if the lower dose works just as well to restore platelet counts but causes fewer side effects. About 76 children will take part and be monitored with blood tests and imaging.